Benzinga | Aug 10, 2021 06:16AM EDT

Nautilus Biotechnology Q2 EPS $(0.19) Misses $(0.09) Estimate

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.09) by 111.11 percent.